Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 3:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 98 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CR + placebo Clear all
Completed Phase 4 Interventional

Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)

NCT00296790
View directory record Official record
Conditions
Insomnia
Interventions
zolpidem tartrate
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years to 64 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 12, 2007 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT00797966
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
OPC-34712, Placebo, ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
50
States / cities
Arcadia, California • Beverly Hills, California • Escondido, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 7, 2026, 3:46 AM EDT
Recruiting Not applicable Interventional

Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder

NCT07318480
View directory record Official record
Conditions
Cocaine Use Disorder, Cocaine Dependence, Substance Use Disorder (SUD)
Interventions
Transcranial Direct Current Stimulator (tDCS), Cognitive Reappraisal Training
Device · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 4 Interventional Results available

Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack

NCT01130103
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Paroxetine, Prolonged Exposure Therapy
Drug · Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

NCT00027703
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions
gemcitabine hydrochloride, cisplatin, bevacizumab, placebo, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure

NCT00323037
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
carvedilol controlled release, carvedilol immediate release
Drug
Lead sponsor
CTI-1, LLC
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
75
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 4 Interventional Results available

Reducing Suicidal Ideation Through Insomnia Treatment

NCT01689909
View directory record Official record
Conditions
Insomnia, Depression, Suicidal Ideation
Interventions
Zolpidem-CR, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Augusta, Georgia • Durham, North Carolina • Wake Forest, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 7, 2026, 3:46 AM EDT
Terminated Phase 4 Interventional Results available

Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD)

NCT01555554
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
Propranolol Hydrochloride, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Medications for Stopping Cocaine Dependence and Preventing Relapse

NCT00218023
View directory record Official record
Conditions
Cocaine Abuse, Cocaine-Related Disorders
Interventions
Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 4 Interventional

Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome

NCT00610610
View directory record Official record
Conditions
Fibromyalgia Syndrome
Interventions
Paroxetine CR, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity

NCT00339014
View directory record Official record
Conditions
Obesity
Interventions
Zonisamide CR and Bupropion SR, Placebo
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Fairhope, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

NCT02035267
View directory record Official record
Conditions
Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions
Deoxycholic Acid, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Newport Beach, California • San Francisco, California • West Hollywood, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Not applicable Interventional

Using Neurostimulation to Accelerate Change in Misophonia: a Pilot Study

NCT06333925
View directory record Official record
Conditions
Misophonia, Emotion Dysregulation, Sensory Processing Disorder, Auditory Over Responsivity, Anxiety Disorder, Sound Sensitivity
Interventions
High Frequency Repetitive Transcranial Magnetic Stimulation (HF rTMS), Sham Repetitive Transcranial Magnetic Stimulation (sham- rTMS), Cognitive Restructuring
Device · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease

NCT00553969
View directory record Official record
Conditions
Pre-hypertension
Interventions
carvedilol phosphate, lisinopril, carvedilol phosphate and lisinopril, placebo and placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
19 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 7, 2026, 3:46 AM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

NCT05169710
View directory record Official record
Conditions
Depressive Episodes, Bipolar I Depression
Interventions
SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
34
States / cities
Huntsville, Alabama • Bryant, Arkansas • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging

NCT01174056
View directory record Official record
Conditions
Lung Inflammation
Interventions
Zileuton, Pioglitazone placebo, Zileuton placebo, Pioglitazone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years to 44 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Not applicable Interventional Results available

Zolpidem CR and Hospitalized Patients With Dementia

NCT00814502
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Dementia, Vascular, Sleep Disorders, Circadian Dysregulation
Interventions
Zolpidem CR, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 3 Interventional Results available

Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure

NCT00624065
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol controlled release/lisinopril, lisinopril + placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

NCT03066778
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
27
States / cities
Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Not applicable Interventional

A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM

NCT00308451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)
Drug
Lead sponsor
Nutrition 21, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2006 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

NCT03670953
View directory record Official record
Conditions
Parkinson's Disease (Disorder)
Interventions
IR CD-LD, IPX203 ER CD-LD, Placebo Matching IPX203, Placebo Matching IR CD-LD
Drug · Other
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
40 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 2 Interventional Results available

Carvedilol for Psychostimulant Dependence

NCT01171183
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Withdrawal
Interventions
controlled release carvedilol, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 7, 2026, 3:46 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 7, 2026, 3:46 AM EDT
Completed Phase 2 Interventional Results available

A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults

NCT00600067
View directory record Official record
Conditions
Diabetes
Interventions
Phentermine/Topiramate, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 7, 2026, 3:46 AM EDT